For IVD-validated mutation and methylation analysis using Pyrosequencing technology
Compliant with EU IVD Directive 98/79/EC
Reliable quantification of allele representation and methylation status
Sequence information enables discovery of rare mutations
More than one assay can be completed in a single run
1–24 samples can be analyzed in as little as 15 minutes
The PyroMark Q24 MDx uses proven Pyrosequencing technology for real-time, sequence-based detection and quantification for in vitro diagnostic use in Europe. This innovative platform is highly suited for genotyping mutations, evaluating disease-related DNA methylation patterns, validating biomarkers, and other diagnostic-related assays.